The Relative Strength (RS) Rating for BridgeBio Pharma entered a higher percentile Friday, as it got a lift from 61 to 74.
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks compares to the rest of the market.
Decades of market research reveals that the market's biggest winners tend to have an 80 or better RS Rating in the early stages of their moves. See if BridgeBio Pharma can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
BridgeBio Pharma is trying to complete a cup with handle with a 30.51 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
BridgeBio Pharma posted 0% earnings growth in its most recent report, while sales growth came in at -33%.
BridgeBio Pharma earns the No. 270 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and ADMA Biologics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
